Binney Street Capital
Mission:
To accelerate the development of new research and technologies to treat uncurable diseases by investing in Dana-Farber startup companies.
To accelerate the development of new research and technologies to treat uncurable diseases by investing in Dana-Farber startup companies.
Impact:
As Dana-Farber's first venture fund, the investment returns from Binney Street Capital will be used to support new innovation and therapies within and outside of the walls of Dana-Farber.
As Dana-Farber's first venture fund, the investment returns from Binney Street Capital will be used to support new innovation and therapies within and outside of the walls of Dana-Farber.
Recent News:
2023-10-5: Our newest portfolio company, Precede Biosciences, emerges from stealth with $57M in financing to dramatically impact precision medicine with a first-in-class liquid biopsy platform.
2023-8-17: Nextpoint Therapeutics announces first patient dosed in Phase 1a/b Clinical Trial of NPX267, a novel therapeutic targeting KIR3DL3 to reactivate exhausted T and NK cells in HHLA2+ solid tumors.
2023-10-5: Our newest portfolio company, Precede Biosciences, emerges from stealth with $57M in financing to dramatically impact precision medicine with a first-in-class liquid biopsy platform.
2023-8-17: Nextpoint Therapeutics announces first patient dosed in Phase 1a/b Clinical Trial of NPX267, a novel therapeutic targeting KIR3DL3 to reactivate exhausted T and NK cells in HHLA2+ solid tumors.